Pregnancy and Birth

 
Use of Most Contraceptive Methods Decreased from 2019-2022: Daily Dose
May 10, 2024

Your daily dose of the clinical news you may have missed.

Pilot Referral Program May Help Increase Postpartum Visits to Primary Care Clinicians
May 09, 2024

Women referred from obstetrics to primary care postpartum via a pilot program were more likely to attend a PCP visit than nonreferred women.

Severe Maternal Morbidity Associated with Mental Health Risks Post-Delivery: Daily Dose
May 07, 2024

Your daily dose of the clinical news you may have missed.

Use of Most Contraceptive Methods Declined from 2019 to 2022, Except Vasectomies, According to New Data
May 02, 2024

More advanced practice clinicians and fewer physicians are providing contraception services, researchers reported.

Migraine in Pregnancy: Considerations for Treatment
October 27, 2023

An overview of safe treatment options for migraine attacks that may occur during pregnancy for primary care clinicians, here.

7 New Approved Drugs for Primary Care: Q3 2023
October 19, 2023

First nonprescription daily oral contraceptive pill, OTC opioid antagonist nasal spray for opioid overdose, and 5 more FDA-approved drugs primary care clinicians should know about.

ACIP Recommends Maternal RSV Vaccine to Protect Newborns
September 25, 2023

Members of the ACIP voted on Friday to recommend Pfizer’s maternal bivalent RSVpreF vaccine to protect newborns from severe RSV illness.

SSRI Treatment May Decrease Risk for Postnatal Depression-Associated Outcomes for Mother, Child
September 05, 2023

Results from a new study suggest that postnatal SSRI treatment may be beneficial in the long term for both women with postpartum depression and their children.

FDA Approves First RSV Vaccine for Use in Pregnant Individuals to Prevent LRTD in Infants
August 22, 2023

The FDA approved Abrysvo for use in pregnant individuals to prevent LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age.

FDA Approves First Oral Medication for Postpartum Depression
August 07, 2023

The US FDA approved zuranolone 50 mg as the first oral, once-daily treatment for postpartum depression in adults.